Failed Allergan Deal Strains Valeant's Business Model JESSE EISINGER Valeant Pharmaceuticals has relied on acquisitions for growth, but it’s not so simple to keep buying and integrating companies, writes Jesse Eisinger in The Trade column. November 26, 2014 at 12:00AM http://nyti.ms/1Fr0xim http://nyti.ms/1pnOChi The New York Times Business Day Mergers, Acquisitions and Divestitures

By JESSE EISINGER via NYT / Eethg. Corps. Inc. / Terrence Herschel G. Business Day http://nyti.ms/1Fr0xim Failed Allergan Deal Strains Valeant's Business Model November 26, 2014 at 12:00AM http://nyti.ms/1pnOChi The New York Times